KDM6A and neoplasm: EZH2‐mediated H3K27me3 and DNMT1‐mediated DNA hypermethylation were attributed to the epigenetic silencing of CCL2, which could be reversed by the combined treatment of EPZ011989 (EZH2 inhibitor) and decitabine (DNMT1 inhibitor); thus, facilitating TAM1 infiltration and tumor killing.[63] Moreover, a recent study demonstrated that lysine‐specific demethylase 6A (KDM6A) repolarized TAMs by regulating the expression of CCL2 and IL‐6.